Aprea Therapeutics(APRE.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Aprea Therapeutics
APRE.US
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
1.813 T
APRE.USMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update
D
BiotechnologyIndustry
Industry Ranking309/386
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-41.85%E
    • Profit Margin-9696.04%E
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY-90.40%E
    • Net Profit YoY15.10%C
    • Total Assets YoY135.45%A
    • Net Assets YoY150.97%A
  • Cash ScoreD
    • Cash Flow Margin100.55%C
    • OCF YoY-90.40%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio11.12%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target

    Tip Ranks·
    US
    APRE
    -6.18%
    US
    SBIO
    -0.21%
    US
    LABD
    -0.57%
    Tip Ranks·
    US
    APRE
    -6.18%
    US
    SBIO
    -0.21%
    US
    LABD
    -0.57%

    Key facts: APRE APR‑1051, ATRN‑119 progress; Q1 loss $0.22

    TradingView·
    US
    APRE
    -6.18%
    US
    PBE
    +0.37%
    US
    FBT
    +1.00%
    TradingView·
    US
    APRE
    -6.18%
    US
    PBE
    +0.37%
    US
    FBT
    +1.00%

    Aprea Therapeutics, Inc. 1Q 2026: Revenue $0 EPS $(0.22) — 10-Q Summary

    TradingView·
    US
    APRE
    -6.18%
    US
    XBI
    +0.28%
    US
    PBE
    +0.37%
    TradingView·
    US
    APRE
    -6.18%
    US
    XBI
    +0.28%
    US
    PBE
    +0.37%

    Aprea Therapeutics | 8-K: FY2026 Q1 Revenue Meets Estimate at USD 0

    Earnings Watch·
    US
    APRE
    -6.18%
    Earnings Watch·
    US
    APRE
    -6.18%

    Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

    Unusual Whales·
    US
    APRE
    -6.18%
    US
    SBIO
    -0.21%
    US
    FBT
    +1.00%
    Unusual Whales·
    US
    APRE
    -6.18%
    US
    SBIO
    -0.21%
    US
    FBT
    +1.00%
    © 2026 Longbridge｜Disclaimer